نتایج جستجو برای: braf

تعداد نتایج: 7505  

Journal: :Expert opinion on pharmacotherapy 2015
Juliet Richman Juan Martin-Liberal Stefan Diem James Larkin

INTRODUCTION BRAF inhibition alone has achieved unprecedented efficacy results in patients affected by BRAF-mutated advanced melanoma. Since these findings, it was postulated that dual inhibition of BRAF and other components of the RAS/RAF/MEK/ERK MAPK pathway (such as MEK) would be superior to BRAF inhibition as monotherapy. A series of recent clinical trials have confirmed this hypothesis. ...

Journal: :International journal of clinical and experimental medicine 2003
Xinying Li Asim B Abdel-Mageed Emad Kandil

BRAF mutation is the most common genetic alternation in thyroid cancer, particularly in papillary thyroid cancer (PTC). Excessive activation of BRAF/MAPK signaling pathway due to BRAF mutation plays a central role in the tumorigenesis and development of PTC. The association of BRAF mutation with poor clinicopathological characteristics of PTC further demonstrated the importance of the BRAF muta...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2015
C Cremolini M Di Bartolomeo A Amatu C Antoniotti R Moretto R Berenato F Perrone E Tamborini G Aprile S Lonardi A Sartore-Bianchi G Fontanini M Milione C Lauricella S Siena A Falcone F de Braud F Loupakis F Pietrantonio

BACKGROUND While the negative prognostic role of BRAF V600E mutation in metastatic colorectal cancer (mCRC) is well established, the impact of BRAF codons 594 and 596 mutations, occurring in <1% of CRCs, is completely unknown. The present work aims to describe clinical, pathological and molecular features and prognosis of BRAF codons 594 and 596 mutant mCRCs, compared with BRAF V600E mutant and...

2013
Lucile Boursault Véronique Haddad Béatrice Vergier David Cappellen Severine Verdon Jean-Pierre Bellocq Thomas Jouary Jean-Philippe Merlio

BRAF inhibitors have demonstrated improvement of overall survival in patients with metastatic melanoma and BRAF(V600) mutations. In order to evaluate BRAF tumor heterogeneity between primary and metastatic site, we have evaluated the performance of immunohistochemistry (IHC) with an anti-BRAF(V600E) antibody in both localization by comparison with high resolution melting analysis followed by Sa...

Journal: :Cancer discovery 2014
Tiffany J Parmenter Margarete Kleinschmidt Kathryn M Kinross Simon T Bond Jason Li Mohan R Kaadige Aparna Rao Karen E Sheppard Willy Hugo Gulietta M Pupo Richard B Pearson Sean L McGee Georgina V Long Richard A Scolyer Helen Rizos Roger S Lo Carleen Cullinane Donald E Ayer Antoni Ribas Ricky W Johnstone Rodney J Hicks Grant A McArthur

UNLABELLED Deregulated glucose metabolism fulfills the energetic and biosynthetic requirements for tumor growth driven by oncogenes. Because inhibition of oncogenic BRAF causes profound reductions in glucose uptake and a strong clinical benefit in BRAF-mutant melanoma, we examined the role of energy metabolism in responses to BRAF inhibition. We observed pronounced and consistent decreases in g...

2008
F Frasca C Nucera M Attard M Stella M Loda V Vella C Giordano R Vigneri

BRAF mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs) that are 80–90% of all thyroid cancers. We evaluated the relationship between BRAF and tumor, host, and environmental factors in PTCs from all geographical areas of Sicily. By PCR, BRAF was investigated in a series of 323 PTCs diagnosed in 2002–2005. The correlation between clinicopathological tumor, ho...

2015
Jun-Ho Ahn Byeal-I Han Michael Lee

The clinical benefits of oncogenic BRAF inhibitor therapies are limited by the emergence of drug resistance. In this study, we investigated the role of a negative regulator of the MAPK pathway, Spry2, in acquired resistance using BRAF inhibitor-resistant derivatives of the BRAF-V600E melanoma (A375P/Mdr). Real-time RT-PCR analysis indicated that the expression of Spry2 was higher in A375P cells...

2013
Alexander Skorokhod Peter Helmbold Benedikt Brors Peter Schirmacher Alexander Enk Roland Penzel

Malignant melanoma is a highly-aggressive type of malignancy with considerable metastatic potential and frequent resistance to cytotoxic agents. BRAF mutant protein was recently recognized as therapeutic target in metastatic melanoma. We present a newly-developed U-BRAF(V600) approach - a universal pyrosequencing-based assay for mutation detection within activation segment in exon 15 of human b...

2013
Erin M. Coffee Anthony C. Faber Jatin Roper Mark J. Sinnamon Gautam Goel Lily Keung Wei Vivian Wang Loredana Vecchione Veerle de Vriendt Barbara J. Weinstein Roderick T. Bronson Sabine Tejpar Ramnik J. Xavier Jeffrey A. Engelman Eric S. Martin Kenneth E. Hung

Purpose: BRAF mutations are associated with poor clinical prognosis in colorectal cancer (CRC). Whereas selective BRAF inhibitors are effective for treatment of melanoma, comparable efforts in CRC have been disappointing. Here, we investigated potential mechanisms underlying this resistance to BRAF inhibitors in BRAF CRC. Experimental Design: We examined phosphatidyl inositol 3-kinase (PI3K)/ma...

Journal: :Anticancer research 2007
Hirotaka Nakayama Akira Yoshida Yoshiyasu Nakamura Hiroyuki Hayashi Youhei Miyagi Nobuyuki Wada Yasushi Rino Munetaka Masuda Toshio Imada

BACKGROUND Activating mutations of the BRAF gene have recently been reported in thyroid carcinomas. In particular, V600E mutation is highly prevalent in papillary thyroid carcinoma (PTC). PATIENTS AND METHODS In this study, the BRAF (V600E) mutation in 54 PTCs was investigated and the relationship between the BRAF mutation and clinicopathological features such as age, gender, tumor size, extr...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید